For instance, Kruit et al. found that a high-dose regimen of IL-2 and IFN-α therapy in combination with lymphokine-activated killer cells caused three treatment-associated deaths in patients suffering from metastatic RCC. This evidence concerns the gene IL2 and renal cell carcinoma.